<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01811368</url>
  </required_header>
  <id_info>
    <org_study_id>367905</org_study_id>
    <secondary_id>UCDCC#233</secondary_id>
    <secondary_id>NCI-2012-02753</secondary_id>
    <nct_id>NCT01811368</nct_id>
  </id_info>
  <brief_title>Zevalin Before Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma</brief_title>
  <official_title>Use of Zevalin to Enhance the Efficacy of Non-Myeloablative Allogeneic Transplantation in Patients With Relapsed or Refractory CD20+ Non-Hodgkin's Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, Davis</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Spectrum Pharmaceuticals, Inc</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, Davis</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase II trial studies how well ibritumomab tiuxetan before donor peripheral blood stem
      cell transplant works in treating patients with relapsed or refractory non-Hodgkin lymphoma.
      Giving rituximab, antithymocyte globulin, and total-lymphoid irradiation (TLI) before a donor
      peripheral blood stem cell transplant helps stop the growth of cancer cells and helps stop
      the patient's immune system from rejecting the donor's stem cells. Also, radiolabeled
      monoclonal antibodies, such as ibritumomab tiuxetan, can find cancer cells and carry
      cancer-killing substances to them without harming normal cells. When the healthy stem cells
      from a donor are infused into the patient they may help the patient's bone marrow make stem
      cells, red blood cells, white blood cells, and platelets. Sometimes the transplanted cells
      from a donor can make an immune response against the body's normal cells. Giving rituximab,
      antithymocyte globulin, and TLI before the transplant together with cyclosporine and
      mycophenolate mofetil after the transplant may stop this from happening. Giving a
      radiolabeled monoclonal antibody before a donor peripheral blood stem cell transplant may be
      an effective treatment for non-Hodgkin lymphoma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. To measure the response conversion (progressive disease [PD]/stable disease [SD] to
      partial response [PR] and complete response [CR]).

      SECONDARY OBJECTIVES:

      I. To assess the time to engraftment/chimerism. II. To assess the rate of acute and chronic
      graft-versus-host disease (GVHD). III. To assess toxicity. IV. To determine the overall
      survival. V. To investigate immune functional and phenotypic analysis. VI. To measure two
      year event free survival (EFS).

      OUTLINE:

      CONDITIONING REGIMEN: Patients receive rituximab intravenously (IV) on days -21 and 14,
      ibritumomab tiuxetan IV on day -14, TLI on days -11 to -7 and -4 to -1, and antithymocyte
      globulin IV over 4-6 hours on days -11 to -7. Patients also undergo TLI on days -11 to -7 and
      -4 to -1.

      TRANSPLANT: Patients undergo allogeneic peripheral blood stem cell transplant (PBSCT) on day
      0.

      GVHD PROPHYLAXIS: Patients receive cyclosporine orally (PO) twice daily (BID) or IV on days
      -3 to 56 with taper to 6 months and mycophenolate mofetil PO BID or IV on days 0-28.

      After completion of study treatment, patients are followed up periodically.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 12, 2013</start_date>
  <completion_date type="Anticipated">January 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response conversion rate (PD/SD to PR and CR)</measure>
    <time_frame>Up to 60 days post-transplant</time_frame>
    <description>Calculated along with 95% confidence intervals (CI). Logistic regression will be used to assess the impact of patient characteristics (e.g., low/high lactate dehydrogenase isoenzyme-3 [LDH] or immunologic correlates) on the response conversion rate.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to engraftment/chimerism</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Estimated using the method of Kaplan and Meier. Comparison of time-to-event endpoints by important subgroups of patients will be made using the logrank test. Cox (proportional hazards) regression will be used to evaluate multivariable predictive models of time-to-event outcomes when proper.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of acute GVHD</measure>
    <time_frame>Up to day 730</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of chronic GVHD</measure>
    <time_frame>Up to day 730</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Up to day 730</time_frame>
    <description>Estimated using the method of Kaplan and Meier. Comparison of time-to-event endpoints by important subgroups of patients will be made using the logrank test. Cox (proportional hazards) regression will be used to evaluate multivariable predictive models of time-to-event outcomes when proper.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EFS</measure>
    <time_frame>2 years</time_frame>
    <description>Comparison of time-to-event endpoints by important subgroups of patients will be made using the logrank test. Cox (proportional hazards) regression will be used to evaluate multivariable predictive models of time-to-event outcomes when proper.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicities</measure>
    <time_frame>Up to day 730</time_frame>
    <description>Toxicities as measured by National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events v4.0</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Refractory Non Hodgkin Lymphoma</condition>
  <condition>Relapsed Non Hodgkin Lymphoma</condition>
  <arm_group>
    <arm_group_label>Treatment (ibritumomab tiuxetan, allogeneic PBSCT)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CONDITIONING REGIMEN: Patients receive rituximab IV on days -21 and 14, ibritumomab tiuxetan IV on day -14, TLI on days -11 to -7 and -4 to -1, and antithymocyte globulin IV over 4-6 hours on days -11 to -7. Patients also undergo TLI on days -11 to -7 and -4 to -1.
TRANSPLANT: Patients undergo allogeneic PBSCT on day 0.
GVHD PROPHYLAXIS: Patients receive cyclosporine PO BID or IV on days -3 to 56 with taper to 6 months and mycophenolate mofetil PO BID or IV on days 0-28.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>rituximab</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (ibritumomab tiuxetan, allogeneic PBSCT)</arm_group_label>
    <other_name>IDEC-C2B8</other_name>
    <other_name>Mabthera</other_name>
    <other_name>Rituxan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ibritumomab tiuxetan</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (ibritumomab tiuxetan, allogeneic PBSCT)</arm_group_label>
    <other_name>Zevalin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>anti-thymocyte globulin</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (ibritumomab tiuxetan, allogeneic PBSCT)</arm_group_label>
    <other_name>ATG</other_name>
    <other_name>ATGAM</other_name>
    <other_name>lymphocyte immune globulin</other_name>
    <other_name>Thymoglobulin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>total nodal irradiation</intervention_name>
    <description>Undergo TLI</description>
    <arm_group_label>Treatment (ibritumomab tiuxetan, allogeneic PBSCT)</arm_group_label>
    <other_name>TLI</other_name>
    <other_name>total lymphoid irradiation</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>peripheral blood stem cell transplantation</intervention_name>
    <description>Undergo allogeneic peripheral blood stem cell transplant</description>
    <arm_group_label>Treatment (ibritumomab tiuxetan, allogeneic PBSCT)</arm_group_label>
    <other_name>PBPC transplantation</other_name>
    <other_name>PBSC transplantation</other_name>
    <other_name>peripheral blood progenitor cell transplantation</other_name>
    <other_name>transplantation, peripheral blood stem cell</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>allogeneic hematopoietic stem cell transplantation</intervention_name>
    <description>Undergo allogeneic peripheral blood stem cell transplant</description>
    <arm_group_label>Treatment (ibritumomab tiuxetan, allogeneic PBSCT)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclosporine</intervention_name>
    <description>Given PO or IV</description>
    <arm_group_label>Treatment (ibritumomab tiuxetan, allogeneic PBSCT)</arm_group_label>
    <other_name>cyclosporin</other_name>
    <other_name>cyclosporin A</other_name>
    <other_name>CYSP</other_name>
    <other_name>Sandimmune</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mycophenolate mofetil</intervention_name>
    <description>Given PO or IV</description>
    <arm_group_label>Treatment (ibritumomab tiuxetan, allogeneic PBSCT)</arm_group_label>
    <other_name>Cellcept</other_name>
    <other_name>MMF</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically or cytologically confirmed relapsed cluster of differentiation (CD)20+
             non-Hodgkin's lymphoma (NHL) (included in this category are follicular grade I, II,
             III, marginal zone, mantle cell, diffuse large B cell, small lymphocytic lymphoma) and
             CD20+ Hodgkin's disease for which standard curative therapy does not exist or is no
             longer effective

          -  Patients must have had at least one prior chemotherapeutic regimen; steroids alone and
             local radiation do not count as regimens; radiotherapy must have been completed at
             least 4 weeks prior to entry into the study; Rituxan alone does not count as a
             regimen; however, Bexxar or Zevalin (ibritumomab tiuxetan) do and patients must have
             completed radioimmunotherapy (RIT) &gt; 12 months prior to enrollment

          -  Karnofsky performance status of â‰¥ 60%

          -  Life expectancy of greater than 3 months

          -  Total bilirubin within institutional normal limits

          -  Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase
             [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT])
             =&lt; 2.5 times institutional upper limit of normal

          -  Creatinine within normal institutional limits OR creatinine clearance &gt;= 60
             ml/min/1.73 m^2 for patients with creatinine levels above institutional normal

          -  Blood counts no restrictions

          -  Patients who had anything less than a CR (PR, SD or progressive disease) to their last
             salvage regimen

          -  Ability to understand and the willingness to sign a written informed consent document

          -  Patients fit for non-myeloablative transplantation or best treatment that have an
             available matched (9/10 or better) related or unrelated donor

          -  Patients who are considered rituximab refractory (defined as progression within 6
             months of their last rituximab-containing regimen)

        Exclusion Criteria:

          -  Patients who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for
             nitrosoureas or mitomycin C) prior to entering the study, rituximab within three
             months (unless there is evidence of progression), or those who have not recovered from
             adverse events due to agents administered more than 4 weeks earlier are excluded; this
             does not include the use of steroids which may continue until two days prior to
             enrollment

          -  Patients may not be receiving any other investigational agents

          -  Failure to obtain insurance/payment authorization for Zevalin, unless the subject
             agrees to cover the cost

          -  Patients with known active brain metastases, other neurological disorders/dysfunction
             or a history of seizure disorder, or other neurological dysfunction should be excluded
             from this clinical trial because of their poor prognosis

          -  Patients who have an uncontrolled infection (presumed or documented) with progression
             after appropriate therapy for greater than one month

          -  Patients with symptomatic coronary artery disease, uncontrolled congestive heart
             failure; left ventricular ejection fraction is not required to be measured, however if
             it is measured, patient is excluded if ejection fraction is &lt; 30%

          -  Patients requiring supplementary continuous oxygen; diffusion capacity of the lung of
             carbon monoxide (DLCO) is not required to be measured, however if it is measured,
             patient is excluded if DLCO &lt; 35%

          -  Patients with clinical or laboratory evidence of liver disease will be evaluated for
             the cause of liver disease, its clinical severity in terms of liver function and
             histology, and for the degree of portal hypertension

          -  Patients with any of the following liver function abnormalities will be excluded:

               -  Fulminant liver failure

               -  Cirrhosis with evidence of portal hypertension or bridging fibrosis

               -  Alcoholic hepatitis

               -  Esophageal varices

               -  A history of bleeding esophageal varices

               -  Hepatic encephalopathy

               -  Uncorrectable hepatic synthetic dysfunction evidenced by prolongation of the
                  prothrombin time

               -  Ascites related to portal hypertension

               -  Chronic viral hepatitis with total serum bilirubin &gt; 3 mg/dL

               -  Symptomatic biliary disease

          -  Pregnant women are excluded from this study

          -  Human immunodeficiency virus (HIV)-positive patients
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joseph Tuscano</last_name>
    <role>Principal Investigator</role>
    <affiliation>UC Davis Comprehensive Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California Davis</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joseph M. Tuscano</last_name>
      <phone>916-734-3089</phone>
      <email>joseph.tuscano@ucdmc.ucdavis.edu</email>
    </contact>
    <investigator>
      <last_name>Joseph M. Tuscano</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 11, 2013</study_first_submitted>
  <study_first_submitted_qc>March 12, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 14, 2013</study_first_posted>
  <last_update_submitted>March 1, 2018</last_update_submitted>
  <last_update_submitted_qc>March 1, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 2, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Mycophenolic Acid</mesh_term>
    <mesh_term>Cyclosporins</mesh_term>
    <mesh_term>Cyclosporine</mesh_term>
    <mesh_term>Thymoglobulin</mesh_term>
    <mesh_term>Antilymphocyte Serum</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

